

FOR IMMEDIATE RELEASE

April 2, 2009

Kissei Pharmaceutical Co., Ltd.

Eisai Co., Ltd.

**Kissei and Eisai Sign License Agreement for *Urief*[®],
A Treatment for Dysuria Associated with Benign Prostatic Hyperplasia
for ASEAN Countries, India, and Sri Lanka**

Kissei Pharmaceutical Co., Ltd. (Headquarters: Matsumoto City, Nagano, President & CEO:

In 2007, both companies signed a license agreement and Eisai obtained the exclusive rights for development and marketing of *Glufast*[®], a rapid acting insulin secretagogue originally discovered and developed by Kissei, in ten ASEAN countries and China. The compound has been filed by Eisai for approval in Indonesia, Malaysia, the Philippines, Singapore, and Thailand.

Contacts:

Public Relations Department,
Kissei Pharmaceutical Co., Ltd.
Tel.: 81-(0)263-25-9523

Public Relations Department,
Eisai Co., Ltd.
Tel.: 81-(0)3-3817-5120